Expert Recommendations on Balancing the Risk and Mitigation Strategies of Veno-occlusive Disease When Treating Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia with Inotuzumab Ozogamicin▼
The publication of this article was initiated and funded by Pfizer. This article is intended for UK Healthcare Professionals only. The Prescribing Information for Inotuzumab Ozogamicin and Adverse Event Reporting can be found within the article.